Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
standard adjuvant chemotherapy + moxifloxacin
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University Cancer Center
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Standard adjuvant chemotherapy + moxifloxacin is a combination treatment regimen being evaluated in a Phase III clinical trial (NCT05115630) led by Sun Yat-sen University for patients with operable breast cancer. The regimen incorporates standard-of-care adjuvant chemotherapy—which may include docetaxel, nab-paclitaxel, cyclophosphamide, or doxorubicin—supplemented with the fluoroquinolone antibiotic moxifloxacin. The study investigates whether the addition of moxifloxacin can improve disease-free survival (DFS), potentially by modulating the microbiome or through other non-canonical effects of the antibiotic in the context of breast cancer treatment.
- Other names
- Standard Adjuvant Chemotherapy Plus MoxifloxacinMoxifloxacin plus standard adjuvant chemotherapy
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)DNATUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on standard adjuvant chemotherapy + moxifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on standard adjuvant chemotherapy + moxifloxacin.